Source:http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/1916
| Predicate | Object |
|---|---|
| rdf:type | |
| rdfs:label |
Zarontin (Solution)
|
| dailymed-instance:dosage |
Zarontin is administered by the oral route. The initial dose for patients 3 to 6 years of age is one teaspoonful (250 mg) per day; for patients 6 years of age and older, 2 teaspoonfuls (500 mg) per day. The dose thereafter must be individualized according to the patient's response. Dosage should be increased by small increments. One useful method is to increase the daily dose by 250 mg every four to seven days until control is achieved with minimal side effects. Dosages exceeding 1.5 g daily, in divided doses, should be administered only under the strictest supervision of the physician. The optimal dose for most pediatric patients is 20 mg/kg/day. This dose has given average plasma levels within the accepted therapeutic range of 40 to 100 mcg/mL. Subsequent dose schedules can be based on effectiveness and plasma level determinations. Zarontin may be administered in combination with other anticonvulsants when other forms of epilepsy coexist with absence (petit mal). The optimal dose for most pediatric patients is 20 mg/kg/day.
|
| dailymed-instance:descripti... |
Zarontin (ethosuximide) is an anticonvulsant succinimide, chemically designated as alpha-ethyl-alpha-methyl-succinimide, with the following structural formula: Each teaspoonful (5 mL), for oral administration, contains 250 mg ethosuximide, USP. Also contains citric acid, anhydrous, USP; FD&C red No. 40; FD&C yellow No. 6; flavor; glycerin, USP; purified water, USP; saccharin sodium, USP; sodium benzoate, NF; sodium citrate, USP; sucrose, NF.
|
| dailymed-instance:clinicalP... |
Ethosuximide suppresses the paroxysmal three cycle per second spike and wave activity associated with lapses of consciousness which is common in absence (petit mal) seizures. The frequency of epileptiform attacks is reduced, apparently by depression of the motor cortex and elevation of the threshold of the central nervous system to convulsive stimuli.
|
| dailymed-instance:activeIng... | |
| dailymed-instance:contraind... |
Ethosuximide should not be used in patients with a history of hypersensitivity to succinimides.
|
| dailymed-instance:supply |
Zarontin is supplied as: NDC 0071-2418-23���1 pint bottles. Each 5 mL of oral solution contains 250 mg ethosuximide in a raspberry flavored base. Store below 30��C (86��F).Preserve in tight containers. Protect from freezing and light.
|
| dailymed-instance:genericDr... | |
| dailymed-instance:activeMoi... | |
| dailymed-instance:inactiveI... |
dailymed-ingredient:FD&C_red_No._40,
dailymed-ingredient:FD&C_yellow_No._6,
dailymed-ingredient:citric_acid,_anhydrous,
dailymed-ingredient:flavor,
dailymed-ingredient:glycerin,
dailymed-ingredient:saccharin_sodium,
dailymed-ingredient:sodium_benzoate,
dailymed-ingredient:sodium_citrate,
dailymed-ingredient:sucrose,
dailymed-ingredient:water
|
| dailymed-instance:precautio... |
General: Ethosuximide, when used alone in mixed types of epilepsy, may increase the frequency of grand mal seizures in some patients. As with other anticonvulsants, it is important to proceed slowly when increasing or decreasing dosage, as well as when adding or eliminating other medication. Abrupt withdrawal of anticonvulsant medication may precipitate absence (petit mal) status.<br/>Information for Patients: Ethosuximide may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a motor vehicle or other such activity requiring alertness; therefore, the patient should be cautioned accordingly. Patients taking ethosuximide should be advised of the importance of adhering strictly to the prescribed dosage regimen. Patients should be instructed to promptly contact their physician when they develop signs and/or symptoms suggesting an infection (eg, sore throat, fever).<br/>Drug Interactions: Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of both drugs are recommended (ethosuximide may elevate phenytoin serum levels, and valproic acid has been reported to both increase and decrease ethosux-imide levels).<br/>Pregnancy: See WARNINGS section.
|
| dailymed-instance:overdosag... |
Acute overdoses produce CNS depression including coma with respiratory depression. A relationship between ethosuximide toxicity and its plasma levels has not been established. The therapeutic range of serum levels is 40 mcg/mL to 100 mcg/mL, although levels as high as 150 mcg/mL have been reported without signs of toxicity.<br/>Treatment: Treatment should include emesis (unless the patient is, or could rapidly become, obtunded, comatose, or convulsing) or gastric lavage, activated charcoal, cathartics, and general supportive measures. Hemodialysis may be useful to treat ethosuximide overdose. Forced diuresis and exchange transfusions are ineffective.
|
| dailymed-instance:genericMe... |
Ethosuximide
|
| dailymed-instance:fullName |
Zarontin (Solution)
|
| dailymed-instance:adverseRe... |
Body As A Whole: Allergic reaction. Gastrointestinal System: Gastrointestinal symptoms occur frequently and include anorexia, vague gastric upset, nausea and vomiting, cramps, epigastric and abdominal pain, weight loss, and diarrhea. There have been reports of gum hypertrophy and swelling of the tongue. Hemopoietic System: Hemopoietic complications associated with the administration of ethosuximide have included leukopenia, agranulocytosis, pancytopenia, with or without bone marrow suppression, and eosinophilia. Nervous System: Neurologic and sensory reactions reported during therapy with ethosuximide have included drowsiness, headache, dizziness, euphoria, hiccups, irritability, hyperactivity, lethargy, fatigue, and ataxia. Psychiatric or psychological aberrations associated with ethosuximide administration have included disturbances of sleep, night terrors, inability to concentrate, and aggressiveness. These effects may be noted particularly in patients who have previously exhibited psychological abnormalities. There have been rare reports of paranoid psychosis, increased libido, and increased state of depression with overt suicidal intentions. Integumentary System: Dermatologic manifestations which have occurred with the administration of ethosuximide have included urticaria, Stevens-Johnson syndrome, systemic lupus erythematosus, pruritic erythematous rashes, and hirsutism. Special Senses: Myopia. Genitourinary System: Vaginal bleeding, microscopic hematuria.
|
| dailymed-instance:indicatio... |
Zarontin is indicated for the control of absence (petit mal) epilepsy.
|
| dailymed-instance:represent... | |
| dailymed-instance:routeOfAd... | |
| dailymed-instance:name |
Zarontin
|